ArticleTherapeutic advances in medical oncology2025
A recurrence risk score model evaluating effects of postmastectomy radiotherapy in breast cancer patients with pathologically negative lymph nodes after neoadjuvant chemotherapy: a multicenter, retrospective study.
Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of postmastectomy radiotherapy (PMRT) in breast cancer patients achieving pathologically negative lymph nodes (ypN0) after neoadjuvant chemotherapy (NAC) remains controversial due to heterogeneous recurrence risks and lack of prospective evidence. Objectives: To evaluate the effects of PMRT in ypN0 patients after NAC. Design: Multicenter retrospective study. Methods: Data of 624 breast cancer patients with ypN0 was assessed to establish a recurrence risk score model based on a disease-free survival (DFS) rate-based multivariate Cox model. Moreover, the locoregional control (LRC), DFS, and overall survival (OS) rates in PMRT and non-PMRT patients were calculated using the Kaplan-Meier method. Results: All patients received a median of four NAC cycles, followed by mastectomy and axillary lymph node dissection; moreover, 257 (41.2%) patients underwent PMRT. Over a median follow-up duration of 74 months, the 5-year LRC, DFS, and OS rates for all patients were 96.6%, 90.1%, and 95.7%, respectively. The differences in the LRC, DFS, and OS rates between PMRT and non-PMRT patients were nonsignificant in the univariate and multivariate analyses. By using our recurrence risk score model based on four factors (i.e., age, clinical N stage, NAC cycle number, and pathological tumor stage after NAC), we stratified the patients into low- and high-risk groups; their 5-year rates of LRC (98.8% vs 93.9%), DFS (95.1% vs 83.8%), and OS (98.4% vs 92.4%) were significantly different (all p < 0.05). PMRT improved LRC (97.6% vs 90.8%, p = 0.027) but not DFS or OS in high-risk patients and had no benefit in low-risk patients. Conclusion: Our recurrence risk score model effectively distinguished ypN0 patients with different recurrence risk stratifications. PMRT improved LRC but not DFS or OS in high-risk patients and low-risk patients did not benefit from PMRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.